HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

• Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients.
  
  
• Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways.
• Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.
  
  

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) --  HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce its subsidiary Pentavere Research Group (“Pentavere”) has achieved a significant milestone with the publication of a paper validating the use of generative AI to identify rare lung cancer patients. The paper, titled "Real-world Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence"⁽¹⁾ marks an important moment in the application of AI in precision oncology. This landmark publication is industry’s first peer-reviewed paper utilizing AI and large language models to identify rare lung cancer patients using real world electronic health record data, supporting precision oncology efforts, and it showcases HEALWELL’s leadership position in developing AI technology applications in healthcare.

Aaron Leibtag, CEO of Pentavere, commented, “Pentavere is pushing the boundaries of innovation in healthcare and leveraging AI to address the most pressing challenges facing patients and healthcare providers. We have harnessed this capability into very productive work with world leading pharma and cancer centers to help optimize patient care in lung cancer. We’ve developed best in class AI that is core to our mission of preventative care. This paper highlights our ability to use generative AI in the real world to unlock key clinical and commercial value."

Dr. Alexander Dobranowski, CEO of HEALWELL, added, "We are immensely proud of the Pentavere team, and the innovative research showcased in this publication. This milestone validates the power of fine-tuned generative AI to drive meaningful insights and transform patient care. This pioneering research will set a new standard for the utilization of advanced technology in healthcare. We remain committed to leveraging AI to improve outcomes for patients worldwide.”

As evidenced in the paper, through the innovative use of AI and large language models, Pentavere has successfully extracted one of the largest population cohorts of advanced rare EGFRexon20 lung cancer patients for use as Real World Evidence. This dataset has provided valuable insights into unmet patient needs, to support more effective cancer treatments.  

Industry leaders such as Johnson & Johnson Innovative Medicine coauthored this paper to support scientific research and improve patient care. Globally recognized clinical oncologists from Princess Margaret Cancer Centre are also authors on this paper and are using this data to enhance the quality of cancer care for their patients.

The ability to analyze the large amounts of unstructured clinical documentation within the electronic health record at scale using generative AI has opened new avenues for improving patient outcomes and advancing precision medicine initiatives.

Footnote:

      (1)   Moulson R, Law J, Sacher A, Liu G, Shepherd FA, Bradbury P, Eng L, Iczkovitz S, Abbie E, Elia-Pacitti J, et al. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence. Current Oncology. 2024; 31(4):1947-1960. /10.3390/curroncol31040146

Dr. Alexander Dobranowski

Chief Executive Officer

HEALWELL AI Inc.

About HEALWELL AI

HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit

About Pentavere

Pentavere Research Group is a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Pentavere's AI system, DARWEN™, identifies patients that are eligible for but not receiving approved medications or interventions, improving outcomes for patients and helping drive appropriate therapy growth and penetration. For more information, visit:

Forward Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential benefits of using generative AI to improve patient outcomes and advance precision medicine initiatives; potential industry applications for Pentavere’s research and generative AI capabilities; and the potential impact of Pentavere’s research on industry standards,, and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as ""improve", "growth", "position", "pushing", "supporting", "advancing" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth and the adoption of new technologies in the industry; anticipated viewership and impact of the publication; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at  The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

For more information:

Pardeep S. Sangha

Investor Relations, HEALWELL AI Inc.

Phone: 604-572-6392